N-Nitrosodiethylamine

CAS Number 55-18-5
Molecular Formula C4H10N2O
Molecular Weight 102.137 g/mol
InChI Key WBNQDOYYEUMPFS-UHFFFAOYSA-N
LogP 0.5
Synonyms
  • Diethylnitrosamine
  • 55-18-5
  • Diethylnitrosoamine
  • NDEA
  • N-Ethyl-N-nitrosoethanamine
  • N,N-Diethylnitrosamine
  • N,N-Diethylnitrosoamine
  • Nitrosodiethylamine
  • Ethanamine, N-ethyl-N-nitroso-
  • Diethylnitrosamide
  • Diethylamine, N-nitroso-
  • Diaethylnitrosamin
  • N-Nitroso-N,N-diethylamine
  • DEN (mutagen)
  • Ethylamine, N-nitrosodi-
  • DENA
  • N,N-diethylnitrous amide
  • RCRA waste number U174
  • N-Diethylnitrosamine
  • NSC 132
  • DEN
  • Nitrosamine, diethyl-
  • N-Nitroso-diaethylamine
  • C4H10N2O
  • UNII-3IQ78TTX1A
  • Diaethylnitrosamin [German]
  • CCRIS 239
  • N-Ethyl-N-nitroso-ethanamine
  • HSDB 4001
  • N-Nitroso-diaethylamine [German]
  • EINECS 200-226-1
  • RCRA waste no. U174
  • BRN 1744991
  • 3IQ78TTX1A
  • 1,1-Diethyl-2-oxohydrazine
  • AI3-62031
  • CHEBI:34873
  • WBNQDOYYEUMPFS-UHFFFAOYSA-N
  • N-Nitrosodiethlamine

Applications:


HPLC Method for Analysis of N-Nitrosodiethylamine on Newcrom R1 Column
N-Nitrosodiethylamine (NDEA) or Diethylnitrosamine is potential carcenogenic agent was found in some blood pressure medications. Those medications were recalled by FDA with the concern of high concentration of the chemical. SIELC developed simple and fast HPLC method to measure presence of NDEA in drug formulations. This UV based method allows to detect ppb level of the compound in solution. Simple mobile phase comprised of acetonitrile (MeCN) and water with detection at 2** nm using Newcrom R1 column can be used to detect both the API and the NDEA.  

Condition

Column Newcrom R1, 4.6x150 mm, 5 µm, 100A
Mobile Phase MeCN - 20-80%
Buffer No
Flow Rate 1.0 ml/min
Detection UV, 232 nm
 

Description

Class of Compounds Carcinogen, Zwitterionic, Hydrophobic
Analyzing Compounds NDMA
 

Application Analytes:

N-Nitrosodiethylamine
Valsartan

HPLC Method for Detection of NDEA in Valsartan Drug Substance
Valsartan products are used to treat high blood pressure and congestive heart failure. On July 13, 2018, FDA announced a recall of valsartan tablets because of the potential for certain products to contain an impurity, N-nitrosodimethylamine (NDMA). Nitrosamine impurities is classified as a probable human carcinogen and is believed to have been introduced into the finished products as a result of the manufacturing process of the drug substance. SIELC developed simple and fast HPLC method to measure presence of NDEA in drug formulations. This UV based method allows to detect ppb level of the compound in solution. Simple mobile phase comprised of acetonitrile (MeCN) and water with detection at 232 nm using Newcrom R1 column can be used to detect both the API and the NDEA.    

Condition

Column Newcrom R1, 4.6x150 mm, 5 µm, 100A
Mobile Phase Gradient MeCN - 10-75%, 12 min
Buffer H3PO4- 0.1%
Flow Rate 1.0 ml/min
Detection UV, 232 nm
 

Description

Class of Compounds Drug, Carcinogen, Zwitterionic, Hydrophilic, Hydrophobic, Ionizable
Analyzing Compounds NDEA,  Valsartan
 

Application Analytes:

N-Nitrosodiethylamine
Valsartan